DE60118571D1 - Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten - Google Patents
Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthaltenInfo
- Publication number
- DE60118571D1 DE60118571D1 DE60118571T DE60118571T DE60118571D1 DE 60118571 D1 DE60118571 D1 DE 60118571D1 DE 60118571 T DE60118571 T DE 60118571T DE 60118571 T DE60118571 T DE 60118571T DE 60118571 D1 DE60118571 D1 DE 60118571D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- pharmaceutical compositions
- topoisomerase inhibitors
- cancer containing
- containing thalidomide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20414300P | 2000-05-15 | 2000-05-15 | |
US204143P | 2000-05-15 | ||
PCT/US2001/015327 WO2001087307A2 (en) | 2000-05-15 | 2001-05-10 | Compositions and methods for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60118571D1 true DE60118571D1 (de) | 2006-05-18 |
DE60118571T2 DE60118571T2 (de) | 2007-02-01 |
Family
ID=22756804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60118571T Expired - Lifetime DE60118571T2 (de) | 2000-05-15 | 2001-05-10 | Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten |
Country Status (19)
Country | Link |
---|---|
US (2) | US7435726B2 (de) |
EP (1) | EP1307197B1 (de) |
JP (1) | JP5409981B2 (de) |
KR (1) | KR100790589B1 (de) |
AR (1) | AR029084A1 (de) |
AT (1) | ATE322266T1 (de) |
AU (2) | AU6147401A (de) |
BR (1) | BR0110877A (de) |
CA (1) | CA2408707C (de) |
DE (1) | DE60118571T2 (de) |
DK (1) | DK1307197T3 (de) |
ES (1) | ES2258084T3 (de) |
HK (1) | HK1054502A1 (de) |
MX (1) | MXPA02011218A (de) |
NZ (1) | NZ522767A (de) |
PT (1) | PT1307197E (de) |
TW (1) | TWI289449B (de) |
WO (1) | WO2001087307A2 (de) |
ZA (1) | ZA200209638B (de) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192360A1 (en) * | 1999-04-14 | 2005-09-01 | Li Chiang J. | Method of treatment of pancreatic cancer |
WO2002064083A2 (en) * | 2000-11-30 | 2002-08-22 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
US6440738B1 (en) * | 2001-02-08 | 2002-08-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of casein kinase 2-beta expression |
ATE318596T1 (de) * | 2001-03-29 | 2006-03-15 | Topotarget As | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii |
JP2005510471A (ja) * | 2001-09-24 | 2005-04-21 | トスク インコーポレーティッド | 減少した毒性のシスプラチン製剤及びそれを使用する方法 |
CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
WO2003047579A1 (en) * | 2001-12-03 | 2003-06-12 | Bayer Pharmaceuticals Corporation | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
AU2002366310A1 (en) * | 2001-12-14 | 2003-06-30 | Kyowa Engineering Co., Ltd. | Method of inducing apoptosis and compositions therefor |
AU2002335472B8 (en) * | 2002-03-26 | 2007-12-20 | Banyu Pharmaceutical Co., Ltd. | Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent |
CN1705439A (zh) * | 2002-04-12 | 2005-12-07 | 细胞基因公司 | 干细胞和祖细胞分化的调节、鉴定及其应用 |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
EP1496880A4 (de) * | 2002-04-24 | 2007-12-12 | Res Dev Foundation | SYNERGISTISCHE WIRKUNGEN VON NUKLEÄREN TRANSKRIPTIONSFAKTOR NF-kB HEMMERN UND ANTINEOPLASTISCHE MITTEL |
NZ570777A (en) * | 2002-05-17 | 2009-04-30 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
CN103393695A (zh) * | 2002-05-17 | 2013-11-20 | 细胞基因公司 | 用于治疗和控制多发性骨髓瘤的方法及组合物 |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
WO2004000229A2 (en) * | 2002-06-24 | 2003-12-31 | Research Development Foundation | Treatment of human multiple myeloma by curcumin |
US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
JP2006510606A (ja) * | 2002-10-15 | 2006-03-30 | セルジーン・コーポレーション | 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物 |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
CA2505003A1 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
MXPA05004780A (es) * | 2002-11-06 | 2005-10-05 | Celgene Corp | Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos. |
JP2006522088A (ja) * | 2003-03-31 | 2006-09-28 | ファイザー・インク | ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩 |
CL2004001004A1 (es) * | 2003-05-19 | 2005-03-18 | Upjohn Co | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. |
US20070270504A1 (en) * | 2003-06-20 | 2007-11-22 | Avalon Pharmaceuticals, Inc. | Identification of Therapeutic Agents Using Genetic Fingerprinting |
US7264819B2 (en) * | 2003-06-23 | 2007-09-04 | Anticancer, Inc. | Lyase treatment for P. carinii |
CA2536380A1 (en) | 2003-08-26 | 2005-02-26 | Research Development Foundation | Osteoclastogenesis inhibitors and uses thereof |
US20050049299A1 (en) * | 2003-08-26 | 2005-03-03 | Aggarwal Bharat B. | Selective inhibitors of stat-3 activation and uses thereof |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
ZA200603718B (en) * | 2003-11-06 | 2007-09-26 | Celgene Corp | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases |
MXPA06006061A (es) * | 2003-12-02 | 2006-08-11 | Celgene Corp | Metodos y composiciones para el tratamiento y manejo de la hemoglinopatia y la anemia. |
EP1947094A3 (de) * | 2003-12-12 | 2009-02-18 | Quiral Quimica Do Brasil | Herstellungsverfahren für Taxanderivate |
EP1722777A2 (de) * | 2004-02-20 | 2006-11-22 | Arqule, Inc. | Verwendung von beta-lapachone zur behandlung von pangreaskarzinomen |
WO2005082356A2 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for the treatment of lung cancer |
EP1732539A2 (de) * | 2004-02-20 | 2006-12-20 | Arqule, Inc. | Verwendung von beta-lapachon zur behandlung von kolonkarzinom |
US7781393B2 (en) | 2004-02-25 | 2010-08-24 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting tumor cell growth |
US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
US20100173864A1 (en) * | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
ES2629682T3 (es) | 2004-03-29 | 2017-08-14 | University Of South Florida | Tratamiento efectivo de tumores y cáncer con fosfato de triciribina |
WO2005110085A2 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
BRPI0418742A (pt) * | 2004-04-14 | 2007-09-11 | Celgene Corp | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit |
CN1946421B (zh) * | 2004-04-27 | 2013-07-17 | 威尔斯达特生物制剂公司 | 使用病毒和喜树碱进行的癌症治疗 |
AU2004319814A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
CA2565446A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
AU2006257664B2 (en) | 2005-06-14 | 2013-01-10 | Protox Therapeutics Incorporated | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
EP1980243A1 (de) * | 2006-02-03 | 2008-10-15 | Takeda Pharmaceutical Company Limited | Liposom-präparat |
EP2019649A4 (de) * | 2006-04-27 | 2012-09-19 | Narmada R Shenoy | Zusammensetzungen und verfahren zur behandlung oder vorbeugung von erkrankungen von körperdurchgangswegen |
CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
EP2014651A1 (de) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Verbindungen und Verfahren zur Modulierung von Rho-GTPasen |
US7893045B2 (en) | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
WO2009058394A1 (en) * | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
SI2219451T1 (sl) * | 2007-11-21 | 2015-02-27 | Oxigene, Inc. | Postopek za zdravljenje hematopoetskih neoplazem |
US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
US8741917B2 (en) | 2009-01-15 | 2014-06-03 | Rutgers, The State University Of New Jersey | Benzo [C] phenanthridines as antimicrobial agents |
US20120059026A1 (en) | 2009-04-30 | 2012-03-08 | University Of Medicine And Dentistry Of New Jersey | Antimicrobial agents |
US8933096B2 (en) | 2010-06-09 | 2015-01-13 | Rugers, The State University of New Jersey | Antimicrobial agents |
US9102617B2 (en) | 2010-06-25 | 2015-08-11 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
KR101369936B1 (ko) * | 2011-12-28 | 2014-03-06 | 연세대학교 산학협력단 | 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물 |
US9822108B2 (en) | 2012-01-13 | 2017-11-21 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
WO2013142712A1 (en) | 2012-03-21 | 2013-09-26 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
WO2014180882A2 (en) * | 2013-05-07 | 2014-11-13 | Universitat De Barcelona | Treatment of brain metastasis from cancer |
US20170080093A1 (en) * | 2013-10-22 | 2017-03-23 | Tyme, Inc. | Tyrosine Derivatives And Compositions Comprising Them |
US9458150B2 (en) | 2013-11-08 | 2016-10-04 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
HUE061382T2 (hu) | 2014-08-22 | 2023-06-28 | Celgene Corp | Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva |
EP3313818B1 (de) | 2015-06-26 | 2023-11-08 | Celgene Corporation | Verfahren zur behandlung von kaposi-sarkom oder ksvh-induziertem lymphom unter verwendung immunmodulatorischer verbindungen und verwendungen von biomarkern |
WO2017031157A1 (en) | 2015-08-18 | 2017-02-23 | Mateon Therapeutics, Inc. | Use of vdas to enhance immunomodulating therapies against tumors |
WO2017147316A1 (en) | 2016-02-25 | 2017-08-31 | Taxis Pharmaceuticals, Inc. | Synthetic processes and intermediates |
BR112019001398A2 (pt) | 2016-07-29 | 2019-05-07 | Janssen Pharmaceutica Nv | métodos para tratamento de câncer de próstata |
KR101851470B1 (ko) | 2016-12-19 | 2018-06-11 | 한림대학교 산학협력단 | 퀘세틴이 함유된 유방암 예방 및 치료를 위한 약제학적 조성물 |
CA3058183A1 (en) | 2017-03-30 | 2018-10-04 | Taxis Pharmaceuticals, Inc. | Synthetic processes and synthetic intermediates |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US5422344A (en) * | 1990-05-08 | 1995-06-06 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Method of treating retroviral infections in mammals |
AU1531492A (en) | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5654312A (en) | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
GB9523493D0 (en) * | 1995-11-16 | 1996-01-17 | British Biotech Pharm | Preparation of allyl succinate derivatives and starting materials therefore |
-
2001
- 2001-05-10 PT PT01935373T patent/PT1307197E/pt unknown
- 2001-05-10 MX MXPA02011218A patent/MXPA02011218A/es active IP Right Grant
- 2001-05-10 WO PCT/US2001/015327 patent/WO2001087307A2/en active IP Right Grant
- 2001-05-10 ES ES01935373T patent/ES2258084T3/es not_active Expired - Lifetime
- 2001-05-10 AU AU6147401A patent/AU6147401A/xx active Pending
- 2001-05-10 JP JP2001583775A patent/JP5409981B2/ja not_active Expired - Fee Related
- 2001-05-10 KR KR1020027015443A patent/KR100790589B1/ko not_active IP Right Cessation
- 2001-05-10 DE DE60118571T patent/DE60118571T2/de not_active Expired - Lifetime
- 2001-05-10 DK DK01935373T patent/DK1307197T3/da active
- 2001-05-10 BR BR0110877-8A patent/BR0110877A/pt active Search and Examination
- 2001-05-10 EP EP01935373A patent/EP1307197B1/de not_active Expired - Lifetime
- 2001-05-10 NZ NZ522767A patent/NZ522767A/en not_active IP Right Cessation
- 2001-05-10 AT AT01935373T patent/ATE322266T1/de active
- 2001-05-10 CA CA2408707A patent/CA2408707C/en not_active Expired - Fee Related
- 2001-05-10 AU AU2001261474A patent/AU2001261474B2/en not_active Ceased
- 2001-05-14 US US09/853,617 patent/US7435726B2/en not_active Expired - Fee Related
- 2001-05-15 AR ARP010102298A patent/AR029084A1/es unknown
- 2001-06-26 TW TW090111620A patent/TWI289449B/zh active
-
2002
- 2002-11-27 ZA ZA200209638A patent/ZA200209638B/en unknown
-
2003
- 2003-08-29 HK HK03106199A patent/HK1054502A1/xx not_active IP Right Cessation
-
2005
- 2005-03-09 US US11/074,849 patent/US20050148524A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001087307A3 (en) | 2002-07-25 |
KR100790589B1 (ko) | 2008-01-02 |
US7435726B2 (en) | 2008-10-14 |
US20020035090A1 (en) | 2002-03-21 |
AU6147401A (en) | 2001-11-26 |
WO2001087307A2 (en) | 2001-11-22 |
MXPA02011218A (es) | 2004-08-19 |
ATE322266T1 (de) | 2006-04-15 |
CA2408707A1 (en) | 2001-11-22 |
EP1307197A2 (de) | 2003-05-07 |
NZ522767A (en) | 2004-07-30 |
BR0110877A (pt) | 2003-03-11 |
CA2408707C (en) | 2010-04-13 |
US20050148524A1 (en) | 2005-07-07 |
ES2258084T3 (es) | 2006-08-16 |
DE60118571T2 (de) | 2007-02-01 |
EP1307197B1 (de) | 2006-04-05 |
JP5409981B2 (ja) | 2014-02-05 |
AU2001261474B2 (en) | 2006-03-09 |
KR20030025922A (ko) | 2003-03-29 |
ZA200209638B (en) | 2003-11-27 |
TWI289449B (en) | 2007-11-11 |
DK1307197T3 (da) | 2006-07-03 |
PT1307197E (pt) | 2006-08-31 |
HK1054502A1 (en) | 2003-12-05 |
JP2003533484A (ja) | 2003-11-11 |
AR029084A1 (es) | 2003-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60118571D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten | |
DE60232251D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von asthma | |
DE50206657D1 (de) | Pharmazeutische zusammensetzung zur behandlung von multiple sklerose | |
DE60031127D1 (de) | Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs | |
DE60035378D1 (de) | Gerät zur Behandlung von Bandscheiben | |
ATE447947T1 (de) | Pharmazeutische zubereitungen zur behandlung von insulinresitenz | |
ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
ATE551100T1 (de) | Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen | |
DE60108080D1 (de) | Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen | |
DE602004022036D1 (de) | Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen | |
EE200100717A (et) | Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks | |
NO20024610L (no) | Synergistiske metoder og blandinger for behandling av kreft | |
ATE468331T1 (de) | Neue cyanopyridine-derivate zur behandlung von krebs und anderer erkrankungen | |
DE60227095D1 (de) | Zusammensetzungen und verfahren zur behandlung von abgebundenem gips | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
ATE265857T1 (de) | Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie | |
ATE207755T1 (de) | Pharmazeutische zusammensetzungen enthaltend lactobacillus brevis und lactobacillus salivarius zur behandlung von vaginainfektionen | |
DE69942680D1 (de) | Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie | |
ATE293971T1 (de) | Pharmazeutische kombinationen enthaltend tegaserod und omeprazole und ihre verwendung zur behandlung gastrointestinaler krankheiten | |
DE60218375D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen | |
HUP0300402A3 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them | |
ATE273276T1 (de) | Cyclobutendion-derivate zur behandlung von artherosclerose | |
DE50010681D1 (de) | Pharmazeutische zubereitung enthaltend zytostatika und elektronenakzeptoren zur behandlung von krebs | |
DE69925578D1 (de) | Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8380 | Miscellaneous part iii |
Free format text: DIE ORTSANGABE BEIM ANMELDER WURDER GEAENDERT IN SUMMIT. |